Generic Medicine Info
Special Precautions
Marked improvements in lung oxygenation and compliance may occur within minutes of administration; frequent and appropriate adjustments to oxygen delivery and ventilator settings may be required to avoid hyperoxia. Premature neonates. Use of beractant in neonates <600 g or >1,750 g birth weight has not been evaluated in controlled clinical trials.
Adverse Reactions
Significant: Transient bradycardia and oxygen desaturation; increased risk of nosocomial sepsis (post-treatment); transient rales and moist breath sounds; endotracheal tube obstruction by mucous secretions.
General disorders and administration site conditions: Rarely, pallor.
Nervous system disorders: Intracranial haemorrhage.
Respiratory, thoracic and mediastinal disorders: Pulmonary haemorrhage. Rarely, hypocapnia, hypercapnia, apnoea, endotracheal tube reflux.
Vascular disorders: Rarely, hypertension, hypotension, vasoconstriction.
Monitoring Parameters
Closely monitor continuous ECG and arterial or transcutaneous systemic oxygen and carbon dioxide (CO2) measurements during administration; arterial blood gases after administration.
Mechanism of Action: Beractant, an exogenous pulmonary surfactant, is a modified bovine lung extract containing mainly phospholipids. It replaces deficient or ineffective endogenous lung surfactant in neonates with or at risk of developing respiratory distress syndrome (RDS). Beractant acts by reducing the surface tension between air and alveolar surfaces, thereby stabilising the alveoli against collapse during respiration and increasing alveolar ventilation.
Onset: Improved oxygenation: Within minutes.
Distribution: Rapidly distributes to the alveolar surfaces.
Store between 2-8°C. Do not freeze. Protect from light. Do not shake. Recommendations on the stability and storage of unopened vials once warmed may vary between countries. Refer to detailed product guidelines.
MIMS Class
Other Drugs Acting on the Respiratory System
Anon. Beractant (Pediatric and Neonatal Lexi-Drugs). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 08/05/2023.

Anon. Beractant. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 24/05/2023.

Beractant. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. Accessed 24/05/2023.

Buckingham R (ed). Pulmonary Surfactants. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 08/05/2023.

Paediatric Formulary Committee. Beractant. BNF for Children [online]. London. BMJ Group, Pharmaceutical Press, and RCPCH Publications. Accessed 08/05/2023.

Survanta 25 mg/mL Suspension (AbbVie Ltd.). MHRA. Accessed 08/05/2023.

Survanta Intratracheal Suspension (AbbVie Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 24/05/2023.

Survanta Suspension (AbbVie Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 08/05/2023.

Disclaimer: This information is independently developed by MIMS based on Beractant from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Survanta
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in